Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Option-To-Acquire In Medical Device Deals Rarely Gets Exercised

This article was originally published in Start Up

Executive Summary

For a device start-up, an option to acquire presents a clear path to liquidity, but there are drawbacks. An analysis of deals in Elsevier’s Strategic Transactions suggests the importance of such options to the overall merger and acquisition ecosystem might be overblown.

You may also be interested in...



Neuromodulation Start-Ups: Abundant Funding, Slow Exits

The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.

Device/Diagnostics Quarterly Deal Statistics, Q4 2013

Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.

Hospitals, Insurers Enjoy Growing Influence As VCs

Over a decade ago, hospital companies began establishing venture capital funds to ride shotgun with institutional VCs, hoping to get a glimpse of health care’s future. Today, under health care reform, VC groups sponsored by providers and payors increasingly find themselves in the driver’s seat, looking for the start-ups that might have solutions to the industry’s biggest problem – cost.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT037762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel